8-K: Novocure Q3 2025 Revenue Up 8%, Pancreatic Cancer PMA Filed

Novocure reported an 8% increase in Q3 2025 net revenues to $167.2 million, driven by active patient growth, and announced the FDA acceptance of its PMA application for pancreatic cancer.

Summary

• Total net revenues for the third quarter ended September 30, 2025, were $167.2 million, an 8% increase compared to the same period in 2024.
• The revenue increase was primarily driven by active patient growth and included $3.3 million in exchange rate benefits.
• As of September 30, 2025, there were 4,416 total active patients on TTFields therapy globally.
• Net loss for the quarter was $37.3 million, resulting in a loss per share of $0.33.
• Adjusted EBITDA for the quarter was $(3.0) million.
• Cash, cash equivalents, and short-term investments totaled $1,033.5 million as of September 30, 2025.
• The U.S. Food and Drug Administration (FDA) accepted Novocure's Premarket Approval (PMA) application for TTFields therapy for locally advanced pancreatic cancer in August 2025.
• Optune Gio prescriptions for glioblastoma increased by 7% year-over-year to 1,675 in the quarter.
• Active Optune Gio patients increased by 5% year-over-year to 4,277 as of September 30, 2025.
• Optune Lua received 130 prescriptions in the quarter, with 109 for non-small cell lung cancer (NSCLC) and 21 for malignant pleural mesothelioma (MPM).
• As of September 30, 2025, there were 139 active Optune Lua patients (100 NSCLC, 39 MPM).
• Novocure announced coverage of Optune Gio through the Spanish National Health System for newly diagnosed glioblastoma in August 2025.
• Approval for Optune Lua use in NSCLC was received from the Japanese Ministry of Health, Labour and Welfare in September 2025.

Sentiment

Score: 5

Explanation: While Novocure demonstrated solid revenue growth and significant progress in its clinical pipeline and geographic expansion, the quarter saw a deterioration in profitability with an increased net loss and negative Adjusted EBITDA, alongside a decline in gross margin. The strong cash position and regulatory advancements provide a positive long-term outlook, but current financial performance indicates challenges in achieving profitability.

Positives

• Net revenues increased by 8% year-over-year to $167.2 million, indicating continued commercial growth.
• Active patient growth contributed significantly to the revenue increase, demonstrating expanding therapy adoption.
• The PMA application for TTFields therapy in locally advanced pancreatic cancer was accepted by the FDA, marking a key regulatory milestone.
• Optune Gio prescriptions for glioblastoma increased by 7% year-over-year, and active patients grew by 5%, showing sustained demand.
• Geographic expansion was successful with Optune Gio coverage in the Spanish National Health System and Optune Lua approval in Japan for NSCLC.
• The company maintains a strong liquidity position with $1,033.5 million in cash, cash equivalents, and short-term investments.

Negatives

• Net loss for the quarter increased to $37.3 million from $30.57 million in the prior year.
• Adjusted EBITDA turned negative to $(3.0) million, compared to $1.73 million in the prior year.
• Gross margin decreased to 73% from 77% in the prior year, impacted by new product rollouts, pre-reimbursement costs for NSCLC, and increased tariffs.
• A $2.9 million expense was recognized for an inventory obsolescence provision for Optune Lua arrays.
• General and administrative expenses increased by 15% year-over-year, driven by higher share-based compensation and personnel/professional services for company build-out.
• Financial income (expenses), net decreased by 43% year-over-year, from $10.507 million to $5.999 million.

Risks

• Gross margin is under pressure due to the continued roll-out of the Head Flexible Electrode (HFE) transducer array for Optune Gio, costs associated with treating NSCLC patients prior to establishing broad reimbursement, and increased tariffs.
• The company recognized a $2.9 million expense related to an inventory obsolescence provision for Optune Lua arrays, indicating potential inventory management challenges or slower-than-expected adoption.
• Increased research, development, and clinical study expenses are driven by product development and regulatory costs for PMA applications, which may not result in timely approvals or commercial success.
• Future performance is subject to general financial, economic, environmental, regulatory, and political conditions, as well as specific risks related to clinical trial progress, regulatory approval, market prospects, and third-party payer coverage.

Future Outlook

Novocure anticipates submitting a PMA application to the FDA for brain metastases from NSCLC in Q4 2025, based on results from the Phase 3 METIS clinical trial. Topline data readouts are expected in Q1 2026 for the Phase 2 PANOVA-4 clinical trial in metastatic pancreatic cancer and in Q2 2026 for the Phase 3 TRIDENT clinical trial in newly diagnosed glioblastoma. The company aims to have four indications in the market by year-end 2026 and remains sharply focused on reaching profitability and expanding patient impact.

Management Comments

• Ashley Cordova, CEO, stated: "Q3 was a solid quarter with steady commercial execution in glioblastoma, geographic expansion, and material progress for our clinical and product development pipelines."
• Ashley Cordova, CEO, also commented: "With four indications expected in market by year-end 2026, we are well on our way to becoming a platform therapy company – and we remain sharply focused on reaching profitability and expanding patient impact."

Industry Context

Novocure operates in the highly specialized and competitive oncology medical device sector, focusing on Tumor Treating Fields (TTFields) therapy. The company's progress in securing regulatory approvals for new indications like pancreatic cancer and NSCLC brain metastases, alongside geographic expansion into markets like Spain and Japan, positions it to broaden its market reach and diversify its revenue streams beyond its established glioblastoma treatment. The stated focus on becoming a 'platform therapy company' suggests a strategic alignment with broader industry trends towards leveraging core technologies across multiple cancer types and personalized medicine.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Mixed impact due to revenue growth and pipeline progress offset by increased losses and negative EBITDA. Long-term value creation potential from new indications remains.
• Patients: Positive impact through expanded access to TTFields therapy in new geographies (Spain, Japan) and potential new indications (pancreatic cancer, NSCLC brain metastases), offering new treatment options.
• Employees: Increased personnel and professional services expenses suggest continued company build-out and investment in digital infrastructure, potentially indicating growth opportunities and job stability.
• Customers (Healthcare Providers): Expanded product approvals and reimbursement coverage facilitate broader adoption of TTFields therapy, simplifying access for patients.
• Creditors: The strong cash position of over $1 billion provides financial stability, mitigating immediate concerns despite current losses.

Next Steps

• Submit a PMA application to the FDA for brain metastases from NSCLC (METIS trial results) in Q4 2025.
• Anticipate topline data readout from the Phase 2 PANOVA-4 clinical trial in metastatic pancreatic cancer in Q1 2026.
• Anticipate topline data readout from the Phase 3 TRIDENT clinical trial in newly diagnosed glioblastoma in Q2 2026.
• Continue steady commercial execution in glioblastoma and geographic expansion.
• Remain sharply focused on reaching profitability and expanding patient impact.
• Work towards having four indications in the market by year-end 2026.

Key Dates

Recommendation

While Novocure demonstrated strong revenue growth and made significant progress in its clinical pipeline and geographic expansion, the quarter's financial performance showed a notable deterioration in profitability, with an increased net loss and negative Adjusted EBITDA. The decline in gross margin and increased operating expenses are concerning. However, the company maintains a robust cash position and has critical regulatory milestones approaching, which could drive future growth. Given the mixed financial results and the long-term potential from pipeline advancements, a 'hold' recommendation is appropriate, advising investors to monitor upcoming clinical trial readouts and progress towards profitability.

Keywords

Novocure, NVCR, Tumor Treating Fields, TTFields, Glioblastoma, Pancreatic Cancer, NSCLC, Malignant Pleural Mesothelioma, Oncology, Medical Device, FDA PMA, Financial Results, Q3 2025